

Rational Optimization of Drug-Target Residence Time: Insights from Inhibitor Binding to the *Staphylococcus aureus* FabI Enzyme–Product Complex

Andrew Chang,^{†,||} Johannes Schiebel,^{‡,§,||} Weixuan Yu,[†] Gopal R. Bommineni,[†] Pan Pan,^{†,#} Michael V. Baxter,[†] Avinash Khanna,^{†,⊥} Christoph A. Sotriffer,[§] Caroline Kisker,^{*,‡} and Peter J. Tonge^{*,†}


[†]Institute for Chemical Biology & Drug Discovery, Department of Chemistry, Stony Brook University, Stony Brook, New York 11794-3400, United States

[‡]Rudolf Virchow Center for Experimental Biomedicine, Institute for Structural Biology, University of Wuerzburg, D-97080 Wuerzburg, Germany

[§]Institute of Pharmacy and Food Chemistry, University of Wuerzburg, Am Hubland, D-97074 Wuerzburg, Germany

S Supporting Information

ABSTRACT: Drug-target kinetics has recently emerged as an especially important facet of the drug discovery process. In particular, prolonged drug-target residence times may confer enhanced efficacy and selectivity in the open *in vivo* system. However, the lack of accurate kinetic and structural data for a series of congeneric compounds hinders the rational design of inhibitors with decreased off-rates. Therefore, we chose the *Staphylococcus aureus* enoyl-ACP reductase (saFabI) — an important target for the development of new anti-staphylococcal drugs — as a model system to rationalize and optimize the drug-target residence time on a structural basis. Using our new, efficient, and widely applicable mechanistically informed kinetic approach, we obtained a full characterization of saFabI inhibition by a series of 20 diphenyl ethers complemented by a collection of 9 saFabI–inhibitor crystal structures. We identified a strong correlation between the affinities of the investigated saFabI diphenyl ether inhibitors and their corresponding residence times, which can be rationalized on a structural basis. Because of its favorable interactions with the enzyme, the residence time of our most potent compound exceeds 10 h. In addition, we found that affinity and residence time in this system can be significantly enhanced by modifications predictable by a careful consideration of catalysis. Our study provides a blueprint for investigating and prolonging drug-target kinetics and may aid in the rational design of long-residence-time inhibitors targeting the essential saFabI enzyme.



When developing lead compounds against a validated drug target, the traditional drug discovery paradigm has focused primarily on optimizing drug-target thermodynamics and *in vivo* pharmacokinetics.¹ However, there has been a recent realization that efficacy and selectivity may also be driven by drug-target kinetics, an overlooked dimension in the conventional structure–activity relationship (SAR) profile.^{1–3} In particular, drug-target residence time, which is defined as the reciprocal of the dissociation rate constant, has been shown to be a promising early stage indicator of *in vivo* drug activity. In agreement with this proposal, 26% of the drugs approved by the FDA between 2001 and 2004 exhibit time-dependent inhibition of their targets.^{1,2}

In a recent study, the residence time of inhibitors targeting the *Francisella tularensis* enoyl-ACP reductase (ftFabI) was strongly correlated with survival rate in a tularemia mouse model of infection.⁴ Understanding the molecular interactions that modulate the rate of dissociation from the FabI enzyme would, therefore, greatly aid in the design of new and effective antibiotics, which are urgently needed.

Staphylococcus aureus is a particularly dangerous pathogen in settings such as hospitals because it is carried by healthy people, mostly in the anterior nares, and is readily transferred to immunocompromised patients.^{5,6} The evolution of antibiotic-resistant strains is, hence, of particularly grave concern since it can very rapidly lead to uncontrolled nosocomial outbreaks.⁷ Unfortunately, methicillin-resistant strains (MRSA) are widespread, and the severity of this problem has been further compounded by the development of resistance against vancomycin, the “drug of last resort”.^{8–10} Thus, there is an emerging need for new drugs against orthogonal targets to combat these constantly adapting pathogens.

The type II fatty acid biosynthesis pathway (FAS II), which is involved in the endogenous production of lipids to be incorporated into the bacterial cell membrane, is a promising source for new drug targets (Figure 1). There has been a recent

Received: April 2, 2013

Revised: May 20, 2013

Published: May 22, 2013






Figure 1. The bacterial fatty acid biosynthesis pathway in *S. aureus*. FabI is the enoyl-ACP reductase in the pathway.

controversy regarding the essentiality of this pathway for septic infections caused by Gram-positive bacteria, such as *S. aureus*, given the lipid-rich environment of human serum.¹¹ However, several studies have emerged in support of FAS II as a valid drug target in *S. aureus* by demonstrating *in vivo* efficacy in animal models of infection and revealing heterogeneity in the incorporation and composition of fatty acids among Gram-positive bacteria.^{12–14} Among the FAS II enzymes, FabI, which catalyzes the final step in the catalytic cycle, has garnered the most attention as an antibacterial target.¹⁵ This was spurred by the discoveries that diazaborines, triclosan and isoniazid, the latter a front-line antituberculosis prodrug, all target this enoyl-ACP reductase.^{15–19} In fact, three separate *S. aureus* FabI (saFabI) inhibitors are currently in clinical trials.^{20–23}

Here, we aim to rationally improve the residence time of saFabI inhibitors by analyzing a series of enzyme–product–drug ternary complex inhibitors using X-ray crystallography and a simple, widely applicable mechanistic approach for kinetics-informed drug discovery efforts. We identified a strong correlation between the affinities of the investigated saFabI diphenyl ether inhibitors and their corresponding residence times, which could be rationalized on a structural basis. The mechanistic insights garnered through a consideration of both catalysis and inhibition may prove significant in the rational improvement of small molecules targeting saFabI.

EXPERIMENTAL PROCEDURES

Compound Synthesis. Synthesis of PT51, PT55, PT52, PT103, PT53, PT01, PT02, PT03, PT04, PT05, and PT13 were described previously.^{24–26} PT68, PT89, PT162, PT446, PT447, PT448, and PT119 were synthesized from their corresponding A-rings with 2-fluoro-benzonitrile in the presence of K_2CO_3 /dimethylformamide at 170 °C. Similarly, PT104 was synthesized from 1-fluoro-2-methoxy-4-nitrobenzene and phenol at 120 °C. Finally, all the compounds were demethylated using BBr_3 . Triclosan was purchased from EMD Millipore Chemicals.

Expression and Purification of saFabI. SaFabI was expressed and purified as described previously.¹⁴ Briefly, we expressed the *safabi* gene in *Escherichia coli* BL21 (DE3), lysed the cells, and isolated the saFabI enzyme via Ni^{2+} affinity chromatography. Finally, size exclusion chromatography yielded >95% pure protein in 20 mM trisodium citrate pH 5.6, 280 mM NaCl, 280 mM potassium glutamate and 1 mM EDTA.

Crystallization, Data Collection, and Structure Determination. As described previously, saFabI was concentrated to

15 mg/mL for cocrystallization experiments.¹⁴ Prior to crystallization, saFabI was incubated for 2 h at 4 °C with a 10-fold molar excess of $NADP^+$ and a 20-fold molar excess of the respective diphenyl ether inhibitor. In vapor diffusion experiments, diffraction-quality crystals of space group P1 were obtained using a precipitant solution composed of 0.1 M Na/K-phosphate pH 6.5 and 35–47% 2-methyl-2,4-pentanediol (MPD). In order to obtain saFabI– $NADP^+$ –PT55 crystals, the protein had to be incubated with the ligands in 25 mM Tris pH 8.0 and 200 mM NaCl at 20 °C prior to concentrating the enzyme from 1 to 15 mg/mL. After directly flash-freezing the crystals in liquid nitrogen, diffraction data were collected to a resolution ranging from 2.15 to 2.50 Å at the MX beamline 14.1 at BESSY II²⁷ ($\lambda = 0.918$ Å, $T = 100$ K) utilizing a MarMosaic 225 detector (PT02, PT04, PT13, PT55, PT68, PT70, and PT119), beamlines ID14–1 ($\lambda = 0.933$ Å, $T = 100$ K) with an ADSC Quantum Q210 detector (PT03) and ID29 ($\lambda = 0.976$ Å, $T = 100$ K) equipped with a Pilatus 6 M detector (PT53) at the ESRF as well as on a Rigaku MicroMax-007 HF X-ray generator ($\lambda = 1.542$ Å, $T = 100$ K) using a R-Axis HTC detector (PT53). Data processing was performed with Imosflm²⁸ and Scala²⁹ (PT02, PT04, PT13, PT55, PT68, PT70, and PT119) or the XDS package³⁰ (PT03, PT53), respectively. The structures were solved by molecular replacement with Phaser³¹ using our previously published saFabI structure as search model (PDB code: 4ALK).¹⁴ Maximum likelihood refinement with Refmac 5³² (including TLS refinement³³) was alternated with model building in Coot³⁴ to obtain the final structures including $NADP^+$ and inhibitors, which were unambiguously identified in the resulting electron density maps. Data collection and refinement statistics are given in Supplementary Table 1, Supporting Information. Structural analysis was performed as described previously,¹⁴ and figures were prepared with PyMOL.³⁵ The model coordinates and structure factors for the saFabI– $NADP^+$ –inhibitor ternary complexes have been deposited in the Protein Data Bank with the codes 4BNF (inhibitor PT02), 4BNG (PT03), 4BNH (PT04), 4BNI (PT13), 4BNJ (PT53), 4BNK (PT55), 4BNL (PT68), 4BNM (PT70), and 4BNN (PT119).

Thermal Shift Assay. ThermoFluor experiments were carried out in 96-well plates (Concord) using the CFX96 Real-Time PCR Detection system and C1000 Thermal Cycler (Bio-Rad). Samples contained 7.4 μ M saFabI, 2.5 mM $NADP^+$ or NADPH, 25 μ M inhibitor (2% DMSO), and 5 \times Sypro Orange (Sigma) in 20 μ L final volume of 50 mM potassium phosphate pH 7.5, 150 mM NaCl, 1 M potassium glutamate, and 8% glycerol. The plates were sealed with Microseal ‘B’ Film (Bio-

Rad) and heated from 25 to 90 °C in increments of 0.2 °C/10 s. Data were processed by the Bio-Rad CFX Manager.

Progress Curve Kinetics. Kinetic experiments were performed on a Cary 100 spectrophotometer (Varian) at 20 °C. Reaction velocities were measured by monitoring the oxidation of NADPH to NADP⁺ at 340 nm ($\epsilon = 6220 \text{ M}^{-1} \text{ cm}^{-1}$). The reaction mixture for forward progress curve experiments has been described previously.¹⁴ In the absence of inhibitor, the time window of progress curve linearity was generally limited by substrate consumption rather than enzyme stability (Supplementary Figure 1). The resulting progress curves were analyzed via the Morrison & Walsh integrated rate equation (eq 1),³⁶

$$A_t = A_0 - v_s t - (v_i - v_s) \left(\frac{1 - e^{-k_{\text{obs}} t}}{k_{\text{obs}}} \right) \quad (1)$$

where A_t and A_0 are the absorbance at time t and time 0, v_i and v_s are the initial and steady state velocities, and k_{obs} is the pseudo-first-order rate constant for the approach to steady-state. K_i^{app} values, which correspond to the steady-state inhibition IC_{50} , were determined by plotting the fractional steady-state velocities as a function of inhibitor concentration and fitting to the isotherm equation (eq 2),

$$\frac{v_s}{v_u} = \frac{1}{1 + ([I]/K_i^{\text{app}})} \quad (2)$$

where v_u is the uninhibited reaction velocity. To calculate k_{-1} , which corresponds to the dissociation rate (k_{off}) of the inhibitor, from each progress curve, we used eq 3.

$$k_{-1} = k_{\text{obs}} \frac{v_s}{v_i} \quad (3)$$

We can also determine k_{-1} by fitting the k_{obs} values from each progress curve to eq 4.

$$k_{\text{obs}} = k_{-1} \left(1 + \frac{[I]}{K_i^{\text{app}}} \right) \quad (4)$$

The commonly used jump dilution assay^{1,36,37} was used to monitor the recovery of enzyme activity following ternary complex formation. 10 μM saFabI, 15 μM inhibitor, and 500 μM NADP⁺ were preincubated overnight at room temperature followed by 1:200 dilution into reaction buffer (50 mM potassium phosphate pH 7.5, 150 mM NaCl, 1 M potassium glutamate, 8% glycerol) containing 1.5 mM crotonyl-CoA (Sigma; Advent Bio) and 350 μM NADPH. The resulting progress curve was fitted to eq 1. All curve fitting was performed using KaleidaGraph Version 4.1.

Kinetic Modeling. A set of ordinary differential equations were constructed based on the kinetic mechanism depicted in Figure 2 and numerically solved using Wolfram Mathematica 8.³⁸ The rationale behind the chosen kinetic parameters is provided in Supplementary Table 2.

³²P Dissociation Kinetics. A mixture of 15 μM saFabI R40Q/K41N/S44L, 20 μM NAD⁺, ³²P-NAD⁺ (800 Ci/mmol), and 200 μM inhibitor in reaction buffer was preincubated at room temperature overnight. Following gel filtration to remove excess free ligand, 500 μL of the mixture was rapidly diluted into 60 mL of reaction buffer to initiate dissociation of the ternary complex. 600 μL aliquots of the diluted mixture were withdrawn at various time points, followed by immediate loading onto an ultrafiltration spin column (Sartorius, 10 kDa)




Figure 2. Mechanistic model for slow-binding kinetics. Three possible mechanisms (A, B, and C) of slow-binding inhibition are depicted. In addition, the detailed kinetic mechanism for inhibition of saFabI by diphenyl ethers is shown below.

and centrifugation at 13 400 rpm for 90 s. The amount of ³²P in the flow through was quantified by a scintillation counter. Data were fit to eq 5,

$$C(t) = C(0) + C_{\text{max}}(1 - e^{-k_{\text{off}} t}) \quad (5)$$

where $C(t)$ and $C(0)$ are the radioactive counts (cpm) at time t and time 0, C_{max} is the maximum radioactive count, and k_{off} is the inhibitor dissociation rate.

RESULTS

Diphenyl Ethers Bind to the E-NADP⁺ Complex Generated via Catalysis. Triclosan and its diphenyl ether analogues are slow-binding inhibitors of the FabI enzyme from a number of organisms, including *S. aureus* and *Francisella tularensis*.^{4,39,40} Although we have previously used the Morrison and Walsh equations to analyze the slow-binding inhibition of ftFabI, we are cognizant that the integrated equations used to analyze progress curve data for slow-binding inhibitors were originally developed for a simple model in which a single-substrate reaction is competitively inhibited by a substrate analogue.^{4,36} To confirm that the Morrison and Walsh integrated equations can be used to analyze the more complex inhibition of FabI, it was first necessary to elucidate a more precise mechanism of inhibition by diphenyl ethers.

FabI catalyzes an ordered Bi Bi reaction, and diphenyl ethers bind uncompetitively with respect to the product NAD(P)⁺.^{39,40} To determine the primary origin of the E-NADP⁺ complex relevant for inhibitor binding, progress curves were obtained for a slow-binding inhibitor (PT53) in the presence of 400 and 2000 μM NADP⁺. These curves were essentially identical (Supplementary Figure 2B), suggesting that the product of the catalytic cycle rather than binding of NADP⁺ to the free enzyme was the dominant source of E-NADP⁺ under the assay conditions. The significance of the E-NADP⁺ complex generated via catalysis for saFabI inhibition has been hinted at in a recent publication⁴¹ and is consistent with the very weak NADP⁺ product inhibition of the free enzyme (Supplementary Figure 2A). Additionally, the onset and degree of inhibition increased when using substrates with higher k_{cat} (data not shown), consistent with a higher steady-state concentration of E-NADP⁺ generated via catalysis.




Figure 3. Diphenyl ethers bind preferably to the E–NADP⁺ binary complex. Representative thermal shift curves of saFabI bound to NADPH, NADP⁺, and/or inhibitor (PT119). The measurement variability is approximately ± 0.2 °C.




Figure 4. Progress curve analysis of saFabI inhibition by diphenyl ether analogues. (A) Representative example of progress curves generated with varying concentrations of PT52 (●). Theoretical curves (—) have been superimposed on the experimental data. These curves were generated using the kinetic parameters in Table 1 and eq 1. R^2 (goodness of fit between theoretical curves and experimental data) = 0.99, 0.95, 0.97, and 0.93 for 250, 500, 750, and 1000 nM PT52, respectively. (B, C) These plots display the corresponding fractional steady-state velocity (v_s/v_0) and pseudo-first-order rate constant (k_{obs}) as a function of inhibitor concentration. Theoretical curves (—) have been superimposed on the experimental data. These curves were generated using the kinetic parameters in Table 1 and eq 2 or 4, respectively. R^2 (goodness of fit between theoretical curves and experimental data) = 0.93 and 0.90 for the IC_{50} and k_{obs} plots, respectively.

Previous studies proposed that diphenyl ethers bind preferentially to the E–NAD(P)⁺ complex but still exhibit potent binding to the E–NAD(P)H complex.^{4,25,40,42,43} However, thermal shift assays revealed exclusive binding of the diphenyl ethers to the saFabI E–NADP⁺ complex (Figure

3). Mechanistic models operating under the assumption that diphenyl ethers bind to the E–NAD(P)H complex are, therefore, erroneous. Instead, the most accurate model is depicted in Figure 2, which was initially proposed for the inhibition of saFabI by triclosan.³⁹ Kinetic rate constants were

rationally derived for each step of the model on the basis of broad experimental data. By numerically solving the system of differential equations, a set of progress curves was generated for a hypothetical inhibitor with predetermined k_1 and k_{-1} . Analysis of this theoretical set of curves by the Morrison and Walsh equations resulted in a reliable estimate of k_{-1} (Supplementary Table 3). This validated the direct use of these equations to analyze the more complex case of FabI inhibition despite its derivation from a simple mechanistic scheme. Surprisingly, accurate estimates of k_{-1} can be obtained at inhibitor concentrations lower than the enzyme concentration without even accounting for tight-binding inhibition. This is because the steady-state population of E–NADP⁺ at the given reaction velocity is much lower than the concentration of free enzyme.

Diphenyl Ethers Bind to saFabI via an Induced-Fit Mechanism. Progress curves corresponding to inhibition of saFabI by diphenyl ethers exhibited curvature characteristic of slow-binding kinetics (Figure 4). Slow-binding inhibition generally encompasses one of three kinetic mechanisms (Figure 2; top).^{2,36,44} The most basic mechanism involves a one-step process with slow inhibitor association accounting for slow formation of the EI complex (Figure 2; Mechanism A). A two-step process, which is most often encountered for slow-binding inhibitors, involves rapid formation of EI followed by a slow induced-fit conformational change to the more potent EI* (Figure 2; Mechanism B). Alternatively, a two-step process may entail a slow conformational change to an enzyme form that rapidly binds inhibitor (Figure 2; Mechanism C). To elucidate the mechanism of slow-binding inhibition, k_{obs} was plotted as a function of inhibitor concentration (Figure 4C). The increasing linear plot unambiguously rules out the possibility of a conformational selection mechanism (Mechanism C).⁴⁵ Typically, this is characteristic of a single-step slow-binding mechanism of inhibition, whereas the two-step induced-fit mechanism is generally characterized by a hyperbolic relationship. However, the one-step mechanism is kinetically indistinguishable from a special case of the two-step mechanism where EI* is much lower in free energy than EI. In this situation, initial inhibition is not detected at low inhibitor concentrations that still affect the steady-state velocity. In a recent report, we structurally characterized the extensive rearrangements that build the active site upon ligand binding.¹⁴ On the basis of these results, binding of the diphenyl ether inhibitors may induce a directional structural change in the enzyme (special case of Mechanism B). Since the results are analyzed in accordance with Mechanism A (Figure 2), k_1 and k_{-1} would, in the special case of Mechanism B, represent the respective overall apparent association and dissociation rate constants between E + I and EI*.

Diphenyl Ether Residence Time Strongly Correlates with Affinity. A detailed understanding of the mechanism and interactions that modulate drug-target residence time is particularly important for future drug discovery programs. However, the rational design of inhibitors with decreased off-rates is still very challenging. This task is further hampered by the lack of accurate kinetic data for large compound series.² Using a mechanistically informed kinetic approach, we analyzed a series of 20 saFabI inhibitors (Table 1). The kinetic barrier to dissociation can be increased by either stabilizing the ground state enzyme–inhibitor complex or destabilizing the transition state (Figure 5A).² Interestingly, the dissociation rate displays a strong linear correlation to K_i in a double logarithmic plot, suggesting that the energetics involved in residence time

Table 1. Kinetic and Thermodynamic Parameters for Inhibitors of saFabI^a

Name	Structure	K_i^{app} (nM)	K_i (nM)	k_1 ($\times 10^{10}$ M ⁻¹ hr ⁻¹) ^b	k_{-1} (hr ⁻¹)	t_R (min) ⁱ
PT51		24515.0 ± 1359.8	18.86 ± 1.05	≥ 0.30	rapid ^c	≤ 1
PT55		1851.8 ± 127.4	1.42 ± 0.10	0.68 ± 0.23	9.67 ± 3.14 ^b 25.36 ± 2.45 ^c	6.2 ^b 2.4 ^c
PT104		1933.4 ± 345.2	1.49 ± 0.27	0.61 ± 0.46	9.03 ± 6.58 ^b	6.6 ^b
PT52		161.2 ± 8.4	0.12 ± 0.01	1.37 ± 0.27	1.70 ± 0.30 ^b 2.33 ± 0.03 ^c 2.13 ± 0.41 ^d	35.3 ^b 25.8 ^c 28.2 ^d
PT103		77.7 ± 9.4	0.06 ± 0.01	1.30 ± 0.25	0.78 ± 0.08 ^b 0.73 ± 0.09 ^d	76.9 ^b 82.2 ^d
PT53		493.7 ± 40.2	0.38 ± 0.03	0.91 ± 0.11	3.46 ± 0.29 ^b 4.53 ± 0.08 ^c	17.3 ^b 13.2 ^c
PT01		120.8 ± 10.1	0.09 ± 0.01	1.01 ± 0.19	0.94 ± 0.14 ^b 0.72 ± 0.08 ^d	63.8 ^b 83.3 ^d
PT02 ^g			0.07	1.33	0.99 ^b 0.57 ± 0.09 ^d	60.9 ^b 105.3 ^d
PT03 ^g			0.04 ^f	0.58	0.20 ^b 0.32 ± 0.17 ^d	300.0 ^b 187.5 ^d
PT04			0.01 ^f	1.30	0.13 ± 0.04 ^d	461.5 ^d
PT05 ^g			0.82	0.25	2.03 ^b 3.74 ± 0.06 ^c	29.6 ^b 16.0 ^c
PT68		145.2 ± 9.1	0.11 ± 0.01	0.79 ± 0.10	0.87 ± 0.07 ^b	68.7 ^b
PT89		123.2 ± 7.9	0.10 ± 0.01	0.68 ± 0.09	0.64 ± 0.06 ^b	93.5 ^b
PT446		1311.3 ± 246.6	1.01 ± 0.19	0.30 ± 0.16	2.99 ± 1.50 ^b	20.1 ^b
PT447		72.0 ± 7.4	0.06 ± 0.01	0.80 ± 0.14	0.44 ± 0.02 ^b 0.47 ± 0.08 ^d	136.4 ^b 127.7 ^d
PT443 ^g			0.05	0.62	0.28 ^b	210.9 ^b
PT119			0.01 ^f	0.80	No recovery ^c 0.08 ± 0.01 ^d	750 ^d
PT13 ^g			0.12	0.73	0.88 ^b	68.5 ^b
TCL		69.2 ± 5.5	0.05 ± 0.01	0.81 ± 0.22	0.43 ± 0.08 ^b	139.5 ^b
PT162 ^g			0.5	0.57	2.66 ^b	22.6 ^b

^aFitting errors are reported for each value in the table, unless otherwise specified. ^bMean value calculated from individual progress

Table 1. continued

curves. Errors reflect the standard deviation from the mean. ^cDetermined by fitting the jump dilution curve to eq 1. ^dDetermined by fitting the ³²P-NAD-based dissociation curve to eq 5. ^eDefined as $\geq 60 \text{ h}^{-1}$. ^fAffinity was calculated using the k_{-1} value obtained from the ³²P-NAD dissociation assay since the dissociation rate was too slow and/or inhibition was too potent. The k_1 value was obtained from forward progress curve analysis. ^gValues estimated from a single progress curve at a single inhibitor concentration. ^hErrors are propagated from K_i and k_{-1} . ⁱResidence time $t_R = 1/k_{-1}$

differentiation are related to stabilization of the final enzyme–inhibitor complex (Figure 5B). In addition, the association rate is very similar across the diphenyl ether series, indicating a similar barrier to the transition state. Importantly, this highlights the fact that the following structural rationale for binding affinity trends also applies to residence time.

Hydrophobic 5-Substituents Enhance Residence Time and Affinity. To obtain a detailed understanding of the kinetic and thermodynamic SAR profile, we solved the structures of saFabI in complex with the oxidized cofactor NADP⁺ and nine diphenyl ethers differing in their substitution pattern (Figure 6, Table 1). All investigated inhibitors bind to the predominantly hydrophobic active site pocket and share a common binding pose stabilized by a π – π -stacking interaction with the NADP⁺ nicotinamide ring (interaction distance of $3.4 \pm 0.1 \text{ \AA}$) and a central hydrogen bond network between Tyr157, the diphenyl ether hydroxyl group and the 2'-OH of the NADP⁺ nicotinamide ribose ($2.6 \pm 0.1 \text{ \AA}$ or $2.5 \pm 0.1 \text{ \AA}$, respectively) (Figure 6). Substituents at the 5-position of the diphenyl ether A-ring bind to an elongated and very lipophilic binding channel mainly composed of Tyr147, Pro192, Val201, Phe204, and Ile207 (Figure 7A,B). Accordingly, we observed clear steric and hydrophobic contributions to binding at the 5-position of the A-ring (Table 1).

PT51, PT55, and PT104 comprise a subset of diphenyl ethers lacking hydrophobic bulk at this position. These compounds are noticeably the least potent of the diphenyl ethers tested. Consistently, a similar trend was recently observed for *E. coli* FabI (ecFabI).⁴¹ Such inhibitors were

previously characterized as rapid-binding, rather than slow-binding, inhibitors of ftFabI.⁴ However, similar to slow-onset inhibitors such as PT52 (PDB entry: 4ALJ),¹⁴ the binding of PT55 to saFabI resulted in the closure of the substrate binding loop, which is believed to be responsible for slow-binding inhibition.¹⁵ In accordance, PT55 and PT104 exhibited clear slow-binding inhibition of saFabI. Slow-binding kinetics may be more difficult to detect with less potent compounds since higher inhibitor concentrations are required to observe inhibition. This may explain why slow-binding inhibition could not be observed for PT51 and may have been missed in the case of ftFabI.⁴

Among compounds with hydrophobic bulk, a steric effect is very prominent. The stabilization conferred by substituting chlorine (PT52; PT447) with bromine (PT103; PT443) provides one such example. Additionally, residence time and affinity increased with aliphatic chain length up to six carbons. Upon elongation of the 5-substituent from methyl (PT53) to ethyl (PT01, PDB entry: 4ALK), propyl (PT02), pentyl (PT03), and hexyl (PT04), the alkyl chain progressively extends into the aforementioned hydrophobic channel thereby explaining the observed k_{off} and K_i trends (Figure 7A,B,E). Beyond this length, however, the alkyl chain is expected to reach the more polar protein surface, rationalizing the decrease in affinity and residence time with PT05. Further striking differences were found between the PT53 and PT04 structures as indicated by an isomorphous difference map. Whereas Ile207 adopts a closed state in the PT53 structure, a conformational change in this gatekeeper residue enables the longer 5-alkyl chains (e.g., the 5-hexyl group of PT04) to bind (Ile207-C_{δ1} shifts by $3.4 \pm 0.4 \text{ \AA}$) (Figure 7C,E). The stepwise opening of the hydrophobic channel upon elongation of the alkyl chain is accompanied by its widening via movements of residues Tyr147 and Val201 (Tyr147-OH shifts by $0.5 \pm 0.1 \text{ \AA}$ and Val201-C_{γ1} by $0.9 \pm 0.1 \text{ \AA}$) (Figure 7D). A comparable mechanism was observed for the *Mycobacterium tuberculosis* homologue InhA during the binding of 5-octyl-2-phenoxyphenol, which induced a shift of Leu218 (corresponding to Ile207 in saFabI).²⁶ In contrast, ftFabI has a methionine at this position, which might explain the preference of the enzyme for




Figure 5. Dissociation kinetics drive changes in thermodynamic affinity. (A) Energy diagram corresponding to Mechanism A in Figure 2. Residence time ($t_R = 1/k_{-1}$) can be prolonged by either stabilizing EI or destabilizing the transition state (TS). (B) A double logarithmic plot depicts a strong correlation between thermodynamic affinity and dissociation kinetics (black) and a weak correlation between association and dissociation kinetics (blue). On each axis, logarithmic values are adjusted such that their mean is equal to zero.




Figure 6. Diphenyl ether binding to the binary saFabI–NADP⁺ complex. Nine diphenyl ether inhibitors are depicted within the saFabI binding pocket (in different colors as defined next to the molecules). All ternary complex structures were superimposed for this purpose. Distances between protein, inhibitor, and cofactor atoms are given as mean values (the standard deviations are defined in the main text). All amino acids within a radius of 6 Å of PT04 except the substrate binding loop residues (194–204) are shown in a light blue surface representation. The substrate binding loop, which is in a similarly closed state for all nine structures, is displayed in gray. Main discrepancies between the depicted saFabI binding pocket of the PT04 structure and the remaining structures are discussed in Figure 7.

PT02.^{4,14} The finding that this part of the saFabI binding pocket is flexible will be important for future inhibitor design efforts.

Diphenyl Ethers Likely Bind in a Deprotonated Form to saFabI. Electrostatics of the A-ring 5-position contribute significantly to saFabI binding. Affinity and residence time increase with more electron-withdrawing substituents in the two series PT51, PT55, PT104 and PT53, PT52. The respective pK_a values for the phenolic hydroxyl group are listed in Supplementary Table 4. We can probe the theoretical contribution of electrostatics to thermodynamic binding if we assume that only the deprotonated oxyanion species can bind to the enzyme. This kinetic simulation resembles the scheme in Figure 2 but also includes a rapid equilibrium inhibitor deprotonation step preceding binding to the E–NADP⁺ binary complex. The equilibrium distribution depends on inhibitor pK_a and buffer pH. Among similarly sized substituents, apparent affinity differences can be almost entirely predicted by pK_a using this theoretical approximation (Supplementary Table 4), suggesting that the inhibitor is bound in a deprotonated state. The slight disparities from experimental values may be rationalized by other factors, such as differences in sterics. This is a theoretical analysis to rationalize the observed magnitude of electrostatic stabilization. In reality, the similar association rate constants among the various compounds suggest that the protonated species can also bind to the enzyme, followed by subsequent deprotonation. The resulting oxyanion species might contribute to the high affinity binding of these inhibitors to saFabI due to the formation of a strong charge-assisted hydrogen bonding network and an electrostatic interaction between the negatively charged phenolic oxygen and the neighboring positive charges of the catalytic triad

residue Lys164 and the oxidized cofactor NADP⁺ (Figure 6). The latter charge-assisted π – π stacking interaction between the inhibitor phenolate ring and the planar oxidized nicotinamide ring of the cofactor might also explain why diphenyl ethers specifically target E–NADP⁺ despite its lower steady-state abundance relative to E–NADPH. On the basis of our kinetic parameters (Supplementary Table 2), the E–NADPH complex is present at more than 300-fold higher concentrations compared to E–NADP⁺ under our assay conditions (Supplementary Table 3). However, further studies are required to unequivocally demonstrate that diphenyl ethers are bound to saFabI in their anionic form and to elucidate when deprotonation might occur.

Small and Slightly Polar 2′-Substituents Contribute to Binding. We also obtained interesting SAR at the B-ring *ortho* position of the diphenyl ether analogues (Table 1). The introduction of a 2′-cyano group enhances affinity and residence time up to 2- and 3-fold, respectively. A methyl substituent (PT70, Figure 8B) also increased affinity (data not shown), while PT13 with an amino substituent displayed decreased affinity (Figure 8A). All investigated 2′-substituents bind to a narrow, elongated, and slightly polar side pocket created by Ala95, Ser197, and the pyrophosphate moiety of NADP⁺ (Figure 8). However, only the linear CN group of PT119 reaches the bottom of this cavity with its polar tip, rendering it ideally suited to fully occupy this space (Figure 8D). In contrast, the steric fit is worse for H, CH₃, Cl (triclosan, PDB code: 4ALI), and NH₂. In particular, the amino substituent is 12-fold less potent as its polar hydrogens have to be desolvated upon binding and cannot engage in geometrically favorable hydrogen bond interactions with surrounding protein residues (Figure 8A). Because of the




Figure 7. Structural changes in saFabI caused by the binding of different 5-alkyldiphenyl ethers. (A) 5-Methyl-2-phenoxyphenol (PT53) is shown as a stick model within its binding pocket. This view shows an intersection through one of the respective saFabI monomers in surface representation. Thus, all parts of the molecule which are in front of an imaginary clipping plane are not visible. (B) The corresponding intersection for the 5-hexyl-2-phenoxyphenol (PT04) structure reveals a binding pocket enlarged around the 5-substituent. (C) Ile207 and the inhibitors of the superimposed PT53 and PT04 structures are shown. Meshes represent selected parts of the NCS-averaged isomorphous difference map at 5σ . Additional experimental electron density for each structure is indicated by the associated color and clearly reveals a conformational change of Ile207. (D) The same map uncovers supplementary movements of Tyr147 and Val201. In addition, the binding of PT04 leads to a reduced occupancy of three water molecules, which are still bound between Tyr147 and Gly202 in the case of PT53. (E) Ile207 and 5-alkyl-2-phenoxyphenols with different alkyl chain lengths are shown. This view was generated via superposition of single monomers of the respective structures (the PT01 structure (PDB code: 4ALK) was published previously¹⁴) and indicates a successive opening movement of Ile207. The color code is defined next to the molecules.




Figure 8. Binding modes of different 2'-substituted saFabI diphenyl ether inhibitors. (A–C) Ala95, Ser197, and NADP⁺ are depicted in stick representation (gray) along with the B-ring *ortho*-substituted inhibitors PT13, PT70, and PT119 (colored according to Figure 6). Distances are given as mean values (standard deviation is 0.1 Å in all cases). (D) The 2'-cyano group (shown as space filling model) of PT119 fills the saFabI side pocket created by Ala95, Ser197, and NADP⁺ (shown as gray surface) with a good steric fit.

clearly limited space in this region of the saFabI binding pocket, we advocate the usage of small B-ring *ortho* substituents in future drug design studies.

Alternative Methods Confirm the Drug-Target Dissociation Rates. Direct dissociation methods were used to

further validate the forward progress curve-based kinetic characterization of diphenyl ethers. In the jump dilution assay, saFabI was preincubated overnight with inhibitor in the presence of NADP⁺ prior to dilution into buffer containing substrate. For less potent inhibitors, dilution allows for full




Figure 9. Direct measurements of inhibitor dissociation. (A) Experimental jump dilution progress curves (●) are shown for the preformed saFabI–NADP⁺–PT55, saFabI–NADP⁺–PT52 and saFabI–NADP⁺–PT447 ternary complexes. Theoretical curves (—) have been superimposed on the experimental data. These curves were generated using the kinetic parameters in Table 1 and eq 1. R^2 (goodness of fit between theoretical curves and experimental data) = 0.98, 0.94, and 0.97 for PT55, PT52, and PT447, respectively. Unlike PT447, there is near recovery to the uninhibited reaction velocity for the less potent compounds PT55 and PT52. (B) Release of ³²P–NAD⁺ from the preformed ternary complex using the saFabI R40Q/K41N/S44L triple mutant is plotted as a function of time. The lines represent the best fits of the points to eq 5 (R^2 = 0.97 and 0.98 for PT52 and PT447, respectively). Fitted k_{off} values are listed in Table 1.

recovery of enzyme activity (Figure 9A; see PT55 and PT52). Thus, for these inhibitors, it was found that the k_{obs} values obtained using jump dilution analysis were in good agreement with k_{-1} values obtained via forward progress curve experiments (Table 1). Unfortunately, compound rebinding complicated the use of jump dilution assays to quantify dissociation of more potent inhibitors, resulting in only partial recovery of enzyme activity. Since the mechanism of inhibition precluded the use of saturating concentrations of substrate to compete against rebinding, k_{obs} for these jump dilution curves overestimated the true k_{-1} . Long-residence-time inhibitors also required a time window extending beyond the feasible assay limits. Nevertheless, given the kinetic parameters derived from progress curve analysis and the radioactivity-based method described below, we can predict the partially recovered jump dilution curve with great accuracy (Figure 9A; see PT447).

To enable accurate characterization of long-residence-time inhibitors, we also developed a ³²P–NAD⁺-based assay of inhibitor dissociation (Figure 9B). This was previously used to study dissociation of diphenyl ethers from the FabI homologue in *M. tuberculosis*, InhA.⁴⁶ Since wild-type saFabI prefers binding to NADP⁺, we used the R40Q/K41N/S44L triple mutant. We showed previously that this mutant behaves exactly as the wild-type enzyme except for an exclusive preference for NAD(H).^{4,14} For all examined inhibitors, we observed good agreement between the k_{-1} values obtained via the different methods. This direct dissociation method is strongly preferred for the characterization of long-residence-time inhibitors which have very slow off-rates (Table 1). For instance, PT119 had a residence time exceeding 700 min that could only be accurately measured using this radioactivity-based direct dissociation technique. For this particular inhibitor, progress curve analysis provided a poor estimate of k_{-1} .

DISCUSSION

In the quest for new effective therapeutics against increasingly resistant pathogens, it is crucial to understand the precise mechanisms of both pharmacologic and physiologic protein–ligand interactions. An improved molecular understanding of

drug–target kinetics can be particularly valuable. Therefore, we chose saFabI — an important target for the development of new anti-staphylococcal drugs⁴⁷ — as a model system to rationalize and optimize the drug–target residence time on a structural basis.

A new, multifaceted approach was utilized to obtain a full kinetic characterization of saFabI inhibition by a series of diphenyl ethers. Using a precise, predictive mechanistic model, we can unravel the key kinetic parameters k_1 , k_{-1} , and K_i for any given inhibitor from only a single progress curve at a single inhibitor concentration. All of this information is contained in the uninhibited and steady state velocity and pseudo-first-order rate constant. The amount of time and substrate required for progress curve analysis has traditionally been limiting given the need for multiple progress curves to characterize a single inhibitor. We have, therefore, developed an extremely efficient and information-rich kinetic assay for future drug discovery efforts. The kinetic information attained via forward progress curve analysis was further validated by direct dissociation methods allowing for the accurate characterization of high affinity and long-residence-time saFabI inhibitors.

We found that dissociation rates and thermodynamic affinity are strongly correlated in a double logarithmic plot (Figure 5B). Very recently, a comparable correlation between K_i and k_{off} has been demonstrated for the amino-nucleoside-based inhibitors of the human protein methyltransferase DOT1L.⁴⁸ Interestingly, Maschera and co-workers identified a similar relationship for saquinavir binding to wild-type HIV-protease and three different resistance-conferring mutants.^{1,49} Thus, nature may select for mutations that promote faster inhibitor dissociation as a primary resistance mechanism. The logarithmic values of k_{-1} and K_i are proportional to the dissociation energy barrier of the ligand $\Delta G_{k_{-1}}$ and its free energy of binding ΔG_{k_i} . The energy barrier of dissociation, and hence the residence time, can be increased by either destabilizing the transition state or stabilizing the ground state of the final enzyme–inhibitor complex.²




Figure 10. Diphenyl ethers as transition state analogues of saFabI. The plot depicts the relationship between fatty acyl-CoA k_{cat} (black; values obtained from our previous work¹⁴) and inhibitor affinity, plotted as the reciprocal of K_i (blue), as a function of the carbon chain length. An inhibitor with n carbons at the A-ring 5-position is equivalent to a substrate with $n+3$ carbon chain length, as depicted on the right. Substrates shorter than four carbons in length are catalytically inactive.

Rational optimization of the residence time is usually difficult as the transition state structure is not readily available.² For the saFabI system, an exact knowledge of this transient structure is not essential. On the basis of the observed correlation between k_{off} and K_i , considerations of the saFabI–NADP⁺–inhibitor complex ground state will be sufficient for the rational improvement of both affinity and residence time. We obtained a wealth of structural information explaining the observed residence time and affinity trends. For example, the addition of bulky hydrophobic diphenyl ether 5-substituents or small slightly polar 2'-substituents (e.g. 2'-cyano) leads to a reduced dissociation rate due to a good steric fit within the protein active site (Figures 7 and 8). On the other hand, significant variations in the association rate constants were not observed. Further exploration of diverse A-ring and/or B-ring substituents may provide insight into how to modulate the transition state barrier.

In addition, our data suggest that affinity and residence time in this system can be significantly enhanced by modifications predictable by a careful consideration of catalysis. Utilizing our parameter estimations (Supplementary Table 2), diphenyl ethers have affinities in the low picomolar to low nanomolar range. This is consistent with the expected affinity of transition-state analogues.⁵⁰ Certainly, the deprotonated diphenyl ether resembles an enolate intermediate (Figure 10). This may explain its preference for binding together with the oxidized product NADP⁺. One can, therefore, imagine an enolate-like, late transition state as the rate-limiting barrier in catalysis. In such a scenario, the delocalized system of the diphenyl ether imitates the breaking and forming of substrate bonds on the way to the enolate. In addition, the acidity of the phenol induces a partial negative charge at the hydroxyl oxygen similar to the transition state (Figure 10). As further evidence, the relationship between inhibitor affinity and aliphatic chain length at the A-ring 5-position perfectly reflects the relationship between catalytic activity and substrate chain length (Figure 10). Interestingly, the least potent inhibitor of our series, PT51, corresponds to a non-natural substrate smaller than the initial crotonyl-ACP substrate. In this context, the observed opening of a hydrophobic channel for long-chain 5-alkyldiphenyl ethers suggests that the gatekeeper residue Ile207 might also play a critical role for binding of substrates with chain lengths exceeding six carbon atoms (Figure 7). On the basis of our knowledge of catalysis, we can also predictably increase potency

by stabilizing the oxanion via electron-withdrawing substituents on the A-ring.

Since the diphenyl ethers primarily bind to the E–NADP⁺ binary complex generated via catalysis, we can predict the evolution of unique kinetic mechanisms of resistance involving mutations away from the inhibitor binding site that accelerate product release. In the case of saFabI, selection experiments have resulted in mutations that do, indeed, lie near the NADP⁺ binding pocket, particularly I193S.^{21,40} We believe that this mutation decreases diphenyl ether inhibition by primarily increasing the rate of NADP⁺ dissociation. However, these mutations are likely to come at a cost since the interactions involved in product binding are also important for binding the reduced cofactor. Accordingly, this mutant was also shown to drastically increase the K_m of the NADPH cofactor.⁴⁰

From a thermodynamic perspective, it would seem that there is a disadvantage to having a drug that binds to the enzyme–product complex since enzymes are designed to bind substrates only long enough for catalysis to occur and then release product quickly to allow for additional rounds of catalysis. For this and similar cases of enzyme–product–drug ternary complex inhibition, the focus must be on slowing the dissociation rate of the ternary complex. In the case of saFabI, tighter binding of diphenyl ether transition state analogues corresponds to longer residence times because of minimal perturbations in the kinetic barrier to association. If long residence times correlate with prolonged cellular effects, optimization of residence time may be the key parameter to unlocking *in vivo* efficacy for these series of metabolically labile compounds.⁵¹ In this regard, our rigorously determined SAR will facilitate further optimization of promising drug candidates with high activity against *S. aureus*. The ultimate hope is that our multipronged strategy will be applied to diverse, complex enzyme systems to achieve a thorough understanding of the interplay between structure, catalysis, and the kinetics and thermodynamics of inhibition. We believe it holds great potential to streamline and facilitate the pursuit of rationality in the early stages of the drug discovery process.

■ ASSOCIATED CONTENT

⑤ Supporting Information

Four supplementary tables and two supplementary figures. This material is available free of charge via the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding Author

*(C.K.) Tel.: +49 931 3180381. E-mail: caroline.kisker@virchow.uni-wuerzburg.de. (P.J.T.) Tel.: (631) 632-7907. Fax: (631) 632-7934. E-mail: peter.tonge@stonybrook.edu.

Present Addresses

#(P.P.) Arkema Inc., 900 First Avenue, King of Prussia, PA 19406.

[†](A.K.) Department of Chemistry, University of California at Irvine, Irvine, CA 92697–2025.

Author Contributions

^{||}These authors contributed equally.

Funding

This work was supported in part by the Deutsche Forschungsgemeinschaft (Grants SFB630 to C.K. and C.A.S. and Forschungszentrum FZ82 to C.K.) and by the National Institutes of Health (Grants GM102864, AI044639, and AI070383 to P.J.T.). A.C. was supported by the Chemical Biology Training Program (NIH grant T32GM092714) and by the Medical Scientist Training Program (NIH Grant T32GM008444). J.S. was supported by a grant of the German Excellence Initiative to the Graduate School of Life Sciences, University of Wuerzburg.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We thank the staff at the beamline 14.1 (BESSY II) operated by the Helmholtz-Zentrum Berlin and at the ESRF beamlines ID 14-1 and ID 29 for technical support.

ABBREVIATIONS

ACP, acyl carrier protein; CoA, coenzyme A; FabI, enoyl-ACP reductase; FAS II, type 2 fatty acid biosynthesis; NAD⁺, nicotinamide adenine dinucleotide; NADH, nicotinamide adenine dinucleotide, reduced form; NADP⁺, nicotinamide adenine dinucleotide phosphate; NADPH, nicotinamide adenine dinucleotide phosphate, reduced form; TCL, triclosan; *t_R*, residence time; SAR, structure–activity relationship

REFERENCES

- (1) Copeland, R. A., Pompliano, D. L., and Meek, T. D. (2006) Drug–target residence time and its implications for lead optimization. *Nat. Rev. Drug Discovery* 5, 730–739.
- (2) Lu, H., and Tonge, P. J. (2010) Drug-target residence time: critical information for lead optimization. *Curr. Opin. Chem. Biol.* 14, 467–474.
- (3) Zhang, R., and Monsma, F. (2009) The importance of drug-target residence time. *Curr. Opin. Drug Discovery* 12, 488–496.
- (4) Lu, H., England, K., am Ende, C., Truglio, J. J., Luckner, S., Reddy, B. G., Marlenee, N. L., Knudson, S. E., Knudson, D. L., Bowen, R. A., Kisker, C., Slayden, R. A., and Tonge, P. J. (2009) Slow-onset inhibition of the FabI enoyl reductase from *francisella tularensis*: residence time and in vivo activity. *ACS Chem. Biol.* 4, 221–231.
- (5) Archer, G. L. (1998) *Staphylococcus aureus*: a well-armed pathogen. *Clin. Infect. Dis.* 26, 1179–1181.
- (6) Kluytmans, J., van Belkum, A., and Verbrugh, H. (1997) Nasal carriage of *Staphylococcus aureus*: epidemiology, underlying mechanisms, and associated risks. *Clin. Microbiol. Rev.* 10, 505–520.
- (7) Chambers, H. F., and Deleo, F. R. (2009) Waves of resistance: *Staphylococcus aureus* in the antibiotic era. *Nat. Rev. Microbiol.* 7, 629–641.

- (8) Oliveira, D. C., Tomasz, A., and de Lencastre, H. (2002) Secrets of success of a human pathogen: molecular evolution of pandemic clones of methicillin-resistant *Staphylococcus aureus*. *Lancet Infect. Dis.* 2, 180–189.
- (9) Walsh, C. (1999) Deconstructing vancomycin. *Science* 284, 442–443.
- (10) Weigel, L. M., Clewell, D. B., Gill, S. R., Clark, N. C., McDougal, L. K., Flannagan, S. E., Kolonay, J. F., Shetty, J., Killgore, G. E., and Tenover, F. C. (2003) Genetic analysis of a high-level vancomycin-resistant isolate of *Staphylococcus aureus*. *Science* 302, 1569–1571.
- (11) Brinster, S., Lamberet, G., Staels, B., Trieu-Cuot, P., Gruss, A., and Poyart, C. (2009) Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens. *Nature* 458, 83–86.
- (12) Balemans, W., Lounis, N., Gilissen, R., Guillemont, J., Simmen, K., Andries, K., and Koul, A. (2010) Essentiality of FASII pathway for *Staphylococcus aureus*. *Nature* 463, 83–86.
- (13) Parsons, J. B., Frank, M. W., Subramanian, C., Saenkhram, P., and Rock, C. O. (2011) Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors. *Proc. Natl. Acad. Sci. U. S. A.* 108, 15378–15383.
- (14) Schiebel, J., Chang, A., Lu, H., Baxter, M. V., Tonge, P. J., and Kisker, C. (2012) *Staphylococcus aureus* FabI: Inhibition, Substrate Recognition, and Potential Implications for In Vivo Essentiality. *Structure* 20, 802–813.
- (15) Lu, H., and Tonge, P. J. (2008) Inhibitors of FabI, an Enzyme Drug Target in the Bacterial Fatty Acid Biosynthesis Pathway. *Acc. Chem. Res.* 41, 11–20.
- (16) Baldock, C., Rafferty, J. B., Sedelnikova, S. E., Baker, P. J., Stuitje, A. R., Slabas, A. R., Hawkes, T. R., and Rice, D. W. (1996) A mechanism of drug action revealed by structural studies of enoyl reductase. *Science* 274, 2107–2110.
- (17) Banerjee, A., Dubnau, E., Quemard, A., Balasubramanian, V., Um, K. S., Wilson, T., Collins, D., de Lisle, G., and Jacobs, W. R., Jr. (1994) inhA, a gene encoding a target for isoniazid and ethionamide in *Mycobacterium tuberculosis*. *Science* 263, 227–230.
- (18) Levy, C. W., Roujeinikova, A., Sedelnikova, S., Baker, P. J., Stuitje, A. R., Slabas, A. R., Rice, D. W., and Rafferty, J. B. (1999) Molecular basis of triclosan activity. *Nature* 398, 383–384.
- (19) Zhang, Y. M., White, S. W., and Rock, C. O. (2006) Inhibiting bacterial fatty acid synthesis. *J. Biol. Chem.* 281, 17541–17544.
- (20) Park, H. S., Yoon, Y. M., Jung, S. J., Kim, C. M., Kim, J. M., and Kwak, J. H. (2007) Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor. *J. Antimicrob. Chemother.* 60, 568–574.
- (21) Escaich, S., Prouvensier, L., Saccomani, M., Durant, L., Oxoby, M., Gerusz, V., Moreau, F., Vongsouthi, V., Maher, K., Morrissey, I., and Soulama-Mouze, C. (2011) The MUT056399 inhibitor of FabI is a new antistaphylococcal compound. *Antimicrob. Agents Chemother.* 55, 4692–4697.
- (22) Karlowsky, J. A., Kaplan, N., Hafkin, B., Hoban, D. J., and Zhanel, G. G. (2009) AFN-1252, a FabI inhibitor, demonstrates a *Staphylococcus*-specific spectrum of activity. *Antimicrob. Agents Chemother.* 53, 3544–3548.
- (23) Kaplan, N., Albert, M., Awrey, D., Bardouniotis, E., Berman, J., Clarke, T., Dorsey, M., Hafkin, B., Ramnauth, J., Romanov, V., Schmid, M. B., Thalakada, R., Yethon, J., and Pauls, H. W. (2012) AFN-1252 - Mode of action, in vitro activity and in vivo efficacy of a selective anti-staphylococcal FabI inhibitor. *Antimicrob. Agents Chemother.* 56, 5865–5874.
- (24) am Ende, C. W., Knudson, S. E., Liu, N., Childs, J., Sullivan, T. J., Boyne, M., Xu, H., Gegina, Y., Knudson, D. L., Johnson, F., Peloquin, C. A., Slayden, R. A., and Tonge, P. J. (2008) Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. *Bioorg. Med. Chem. Lett.* 18, 3029–3033.
- (25) Sivaraman, S., Sullivan, T. J., Johnson, F., Novichenok, P., Cui, G., Simmerling, C., and Tonge, P. J. (2004) Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues. *J. Med. Chem.* 47, 509–518.

- (26) Sullivan, T. J., Truglio, J. J., Boyne, M. E., Novichenok, P., Zhang, X., Stratton, C. F., Li, H. J., Kaur, T., Amin, A., Johnson, F., Slayden, R. A., Kisker, C., and Tonge, P. J. (2006) High affinity InhA inhibitors with activity against drug-resistant strains of *Mycobacterium tuberculosis*. *ACS Chem. Biol.* 1, 43–53.
- (27) Mueller, U., Darowski, N., Fuchs, M. R., Forster, R., Hellmig, M., Paithankar, K. S., Puhlinger, S., Steffien, M., Zocher, G., and Weiss, M. S. (2012) Facilities for macromolecular crystallography at the Helmholtz-Zentrum Berlin. *J. Synchrotron Radiat.* 19, 442–449.
- (28) Leslie, A. G. W. (1992) Recent changes to the MOSFLM package for processing film and image plate data. *Joint CCP4 + ESF-EAMCB Newslett. Protein Crystallogr.* 26.
- (29) Evans, P. (2006) Scaling and assessment of data quality. *Acta Crystallogr. D: Biol. Crystallogr.* 62, 72–82.
- (30) Kabsch, W. (1993) Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. *J. Appl. Crystallogr.* 26, 795–800.
- (31) McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., and Read, R. J. (2007) Phaser crystallographic software. *J. Appl. Crystallogr.* 40, 658–674.
- (32) Murshudov, G. N., Vagin, A. A., and Dodson, E. J. (1997) Refinement of macromolecular structures by the maximum-likelihood method. *Acta Crystallogr. D: Biol. Crystallogr.* 53, 240–255.
- (33) Painter, J., and Merritt, E. A. (2006) TLSMD web server for the generation of multi-group TLS models. *J. Appl. Crystallogr.* 39, 109–111.
- (34) Emsley, P., and Cowtan, K. (2004) Coot: model-building tools for molecular graphics. *Acta Crystallogr. D: Biol. Crystallogr.* 60, 2126–2132.
- (35) *The PyMOL Molecular Graphics System*, Version 1.3r1, Schrodinger, LLC, 2010.
- (36) Morrison, J. F., and Walsh, C. T. (1988) The behavior and significance of slow-binding enzyme inhibitors. *Adv. Enzymol. Relat. Areas Mol. Biol.* 61, 201–301.
- (37) Copeland, R. A., Basavapathruni, A., Moyer, M., and Scott, M. P. (2011) Impact of enzyme concentration and residence time on apparent activity recovery in jump dilution analysis. *Anal. Biochem.* 416, 206–210.
- (38) *Mathematica*, Version 8.0, Wolfram Research, Inc., Champaign, IL, 2010.
- (39) Heath, R. J., Li, J., Roland, G. E., and Rock, C. O. (2000) Inhibition of the *Staphylococcus aureus* NADPH-dependent Enoyl-Acyl Carrier Protein Reductase by Triclosan and Hexachlorophene. *J. Biol. Chem.* 275, 4654–4659.
- (40) Xu, H., Sullivan, T. J., Sekiguchi, J.-i., Kirikae, T., Ojima, I., Stratton, C. F., Mao, W., Rock, F. L., Alley, M. R. K., Johnson, F., Walker, S., and Tonge, P. J. (2008) Mechanism and Inhibition of saFabI, the Enoyl Reductase from *Staphylococcus aureus*. *Biochemistry* 47, 4228–4236.
- (41) Gerusz, V., Denis, A., Faivre, F., Bonvin, Y., Oxoby, M., Briet, S., Lefrallie, G., Oliveira, C., Desroy, N., Raymond, C., Peltier, L., Moreau, F., Escaich, S., Vongsouthi, V., Floquet, S., Drocourt, E., Walton, A., Prouvensier, L., Saccomani, M., Durant, L., Genevard, J. M., Sam-Sambo, V., and Soulama-Mouze, C. (2012) From Triclosan toward the Clinic: Discovery of Nonbiocidal, Potent FabI Inhibitors for the Treatment of Resistant Bacteria. *J. Med. Chem.* 55, 9914–9928.
- (42) Sivaraman, S., Zwahlen, J., Bell, A. F., Hedstrom, L., and Tonge, P. J. (2003) Structure-activity studies of the inhibition of FabI, the enoyl reductase from *Escherichia coli*, by triclosan: kinetic analysis of mutant FabIs. *Biochemistry* 42, 4406–4413.
- (43) Marcinkeviciene, J., Jiang, W., Kopcho, L. M., Locke, G., Luo, Y., and Copeland, R. A. (2001) Enoyl-ACP reductase (FabI) of *Haemophilus influenzae*: steady-state kinetic mechanism and inhibition by triclosan and hexachlorophene. *Arch. Biochem. Biophys.* 390, 101–108.
- (44) Copeland, R. A. (2011) Conformational adaptation in drug-target interactions and residence time. *Future Med. Chem.* 3, 1491–1501.
- (45) Tummino, P. J., and Copeland, R. A. (2008) Residence Time of Receptor–Ligand Complexes and Its Effect on Biological Function. *Biochemistry* 47, 8465.
- (46) Luckner, S. R., Liu, N., am Ende, C. W., Tonge, P. J., and Kisker, C. (2010) A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from *Mycobacterium tuberculosis*. *J. Biol. Chem.* 285, 14330–14337.
- (47) Gerusz, V. (2010) Recent Advances in the Inhibition of Bacterial Fatty Acid Biosynthesis. *Annu. Rep. Med. Chem.* 45, 295–311.
- (48) Basavapathruni, A., Jin, L., Daigle, S. R., Majer, C. R., Therkelsen, C. A., Wigle, T. J., Kuntz, K. W., Chesworth, R., Pollock, R. M., Scott, M. P., Moyer, M. P., Richon, V. M., Copeland, R. A., and Olhava, E. J. (2012) Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L. *Chem. Biol. Drug Des.* 80, 971–980.
- (49) Maschera, B., Darby, G., Palu, G., Wright, L. L., Tisdale, M., Myers, R., Blair, E. D., and Furfine, E. S. (1996) Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex. *J. Biol. Chem.* 271, 33231–33235.
- (50) Schramm, V. L. (2011) Enzymatic transition states, transition-state analogs, dynamics, thermodynamics, and lifetimes. *Annu. Rev. Biochem.* 80, 703–732.
- (51) Wang, L. Q., Falany, C. N., and James, M. O. (2004) Triclosan as a substrate and inhibitor of 3'-phosphoadenosine 5'-phosphosulfate-sulfotransferase and UDP-glucuronosyl transferase in human liver fractions. *Drug Metab. Dispos.: Biol. Fate Chem.* 32, 1162–1169.